⚡ Flash Summary
Liven Pharma Limited has received confirmation from the Central Depository Company (CDC) that its Letter of Rights (Right Entitlements) are now eligible as CDS securities. This eligibility is effective from November 24, 2025, as per the CDC’s notice dated November 21, 2025. The announcement facilitates the trading and settlement of these rights entitlements through the Central Depositary System. This move should streamline transactions and potentially broaden investor participation in Liven Pharma’s rights issue.
📌 Key Takeaways
- ✅ Liven Pharma’s Letter of Rights declared CDS eligible.
- 🗓️ Effective date: November 24, 2025.
- 🏢 CDC confirmed eligibility via notice dated November 21, 2025.
- 📄 Refers to rights issue of ordinary shares.
- 🔗 Facilitates trading and settlement through CDS.
- 📜 Follows Regulation 8AA.1.1 and SAA.2.2 of CDC regulations.
- 🤝 Company must fulfill CDC’s procedural requirements.
- ℹ️ Informs TREC holders of the Exchange.
- 🏢 Addresses Pakistan Stock Exchange.
- ✉️ Referenced letter no PSX/C-857-1681 dated September 15, 2025.
🎯 Investment Thesis
Based on the announcement, the recommendation is HOLD. The declaration of CDS eligibility for Liven Pharma’s Letter of Rights is a positive operational development but does not fundamentally alter the investment case. More information on the utilization of the rights and its effects on the company will be needed.
Disclaimer: AI-generated analysis. Not financial advice.